Mereo BioPharma Group plc
MREO
$0.24
-$0.01-4.75%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 0.00 | 500.00K | 500.00K | 500.00K | 500.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00 | 500.00K | 500.00K | 500.00K | 500.00K |
| Cost of Revenue | 0.00 | 132.00K | 132.00K | 132.00K | 132.00K |
| Gross Profit | 0.00 | 368.00K | 368.00K | 368.00K | 368.00K |
| SG&A Expenses | 19.48M | 19.76M | 23.01M | 25.27M | 25.42M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -300.00K | -300.00K | -300.00K | -- | -- |
| Total Operating Expenses | 33.07M | 36.41M | 38.76M | 45.84M | 45.12M |
| Operating Income | -33.07M | -35.91M | -38.26M | -45.34M | -44.62M |
| Income Before Tax | -28.10M | -35.71M | -41.88M | -41.57M | -49.55M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -28.10 | -35.71 | -41.88 | -41.57 | -49.55 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -28.10M | -35.71M | -41.88M | -41.57M | -49.55M |
| EBIT | -33.07M | -35.91M | -38.26M | -45.34M | -44.62M |
| EBITDA | -32.22M | -35.06M | -37.44M | -44.83M | -44.01M |
| EPS Basic | -0.88 | -1.12 | -1.32 | -1.32 | -1.58 |
| Normalized Basic EPS | -0.11 | -0.14 | -0.16 | -0.16 | -0.20 |
| EPS Diluted | -0.88 | -1.12 | -1.32 | -1.32 | -1.58 |
| Normalized Diluted EPS | -0.11 | -0.14 | -0.16 | -0.16 | -0.20 |
| Average Basic Shares Outstanding | 641.15M | 640.32M | 636.82M | 631.75M | 625.79M |
| Average Diluted Shares Outstanding | 128.23M | 128.06M | 127.36M | 126.35M | 125.16M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |